Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
Patents for C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
12/2013
12/24/2013US8614219 Substituted pyrimidin-4-one derivatives
12/24/2013DE112012000828T5 Lichtemittierendes Element The light-emitting element
12/24/2013CA2714181C Ampk modulators
12/24/2013CA2613059C Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect, process for their manufacture and use thereof as medicaments
12/19/2013WO2013188184A1 Inhibitor of jak1 and jak2
12/19/2013WO2013187482A1 Tandem-type organic photoelectric conversion element, and photovoltaic cell using same
12/19/2013WO2013187462A1 Piperidinylpyrazolopyridine derivative
12/19/2013WO2013187258A1 Material for light-emitting element and light-emiting element
12/19/2013WO2013186666A1 Tricyclic compounds as kat ii inhibitors
12/19/2013WO2013186335A1 1,3 -dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
12/19/2013WO2013186334A1 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
12/19/2013WO2013186333A1 1,3 -dihydro- 2h-benzimidazol- 2 -one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
12/19/2013WO2013186332A1 4 - substituted 1, 3 - dihydro - 2h - benzimidazol - 2 - one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
12/19/2013WO2013186159A1 New diazaspirocycloalkane and azaspirocycloalkane
12/19/2013WO2013185353A1 Compound as wnt signaling inhibitor, composition, and use thereof
12/19/2013US20130338219 Terpenoid Spiro Ketal Compounds with LXR Agonists Activity, Their Use and Formulations with Them
12/19/2013US20130338185 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
12/19/2013US20130338184 2-amino-naphthyridine derivatives
12/19/2013US20130338157 Azaindazole compounds and methods of use
12/19/2013US20130338156 Imidazopyridin-2-one derivatives
12/19/2013US20130338153 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
12/19/2013US20130338151 Fused ring analogues of anti-fibrotic agents
12/19/2013US20130338140 Serine/threonine kinase inhibitors
12/19/2013US20130338139 Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones
12/19/2013US20130338138 Azetidine and piperidine compounds useful as pde10 inhibitors
12/19/2013US20130338134 Substituted tricyclic compounds as fgfr inhibitors
12/19/2013US20130338133 Substituted imidazopyridazines
12/19/2013US20130338094 Substituted pyrrolo]2,3-d]pyrimidines
12/19/2013US20130336996 Novel compositions of tlr7 and/or tlr8 agonists conjugated to lipids
12/19/2013CA2876382A1 Piperidinylpyrazolopyridine derivative
12/19/2013CA2875372A1 Compound as wnt signaling inhibitor, composition, and use thereof
12/18/2013EP2674430A1 Amino group-containing pyrrolidinone derivative
12/18/2013EP2674428A1 Modulators of ATP-binding cassette transporters
12/18/2013EP2674417A2 Biaryl PDE4 inhibitors for treating inflammation
12/18/2013EP2674160A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
12/18/2013EP2673275A1 PROCESS FOR OBTAINING COMPOUNDS DERIVED FROM TETRAHYDRO-ß-CARBOLINE
12/18/2013EP2673269A1 Heterocyclic compounds as pi3 kinase inhibitors
12/18/2013EP2672967A1 Compounds and methods for kinase modulation, and indications therefor
12/18/2013EP2521726B1 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as camkii kinases inhibitors for the treatment of cardiovascular diseases
12/18/2013EP2496576B1 Imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
12/18/2013EP2491034B1 Fused heterocyclic compounds as orexin receptor modulators
12/18/2013EP2488521B1 Macrocyclic integrase inhibitors
12/18/2013EP2440542B1 Substituted benzimidazoles, benzonthiazoles and benzoxazoles
12/18/2013EP2440204B1 Nicotinamide compounds useful as kinase modulators
12/18/2013EP2398793B1 Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators
12/18/2013EP2392574B1 Indolyl pyrrolidines for the treatment of cancer
12/18/2013EP2059519B1 Nitrogen-containing heterocyclic compounds and methods of use thereof
12/18/2013EP2020410B1 Pyrido[2,3-d]pyrimidine derivatives, process for their preparation and their therapeutical use
12/18/2013CN103459514A Novel compound having alpha-cyanoacrylate structure, dye, and coloring photosensitive composition
12/18/2013CN103459399A Tetracyclic indole derivatives for treating hepatitis c virus infection
12/18/2013CN103459391A Compounds for electronic devices
12/18/2013CN103459390A Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
12/18/2013CN103459389A 7-(heteroaryl-amino)-6, 7, 8, 9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
12/18/2013CN103459388A Novel furanone derivative
12/18/2013CN103459387A Mesoionic pyrido [1,2 -A] pyrimidine pesticides
12/18/2013CN103459384A Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture
12/18/2013CN103458898A Autophagy inducing compound and use thereof
12/18/2013CN103458865A Composition for external application
12/18/2013CN103450887A Conjugated phenanthroline-pyridine fluorescent reagents as well as preparation method and application thereof
12/18/2013CN103450339A LRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
12/18/2013CN103450337A TRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
12/18/2013CN103450336A KRGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
12/18/2013CN103450334A RGD peptide-modified carbolino-hexahydropyrazine-1,4-diketones and their preparation method, antithrombotic effect and use
12/18/2013CN103450218A Indole tricyclic derivative as CRTH2 receptor antagonist
12/18/2013CN103450200A Preparation method of corynoxine
12/18/2013CN103450199A Theanine-modified carboline acyl amino acid benzyl ester, as well as preparation, anti-tumor activity and application thereof
12/18/2013CN103450198A Imidazo pyrido imidazole-3-substituted benzyl acetates, and synthesis, antineoplastic activities and application thereof
12/18/2013CN103450197A Cyclohexyl tetrahydro imidazo pyrido indole-diketone acetyl amino acids, and synthesis, antithrombotic effect and application thereof
12/18/2013CN103450196A AGDV peptide modified carboline-hexahydropyrazine-1,4-dione, preparation method, antithrombotic effect, and applications thereof
12/18/2013CN103450195A Tetrahydro-beta-carbolinyl-3-formic acid aliphatic chain alcohol esters, and preparation, nano structure, immunosuppression action and application thereof
12/18/2013CN103450194A Tetrahydro-beta-carbolinyl-3-formyl aliphatic chain amines, and preparation, nano structure, immunosuppression action and application thereof
12/18/2013CN103450193A Salt of thiazolyl pyridinopyrimidone derivative
12/18/2013CN103450192A Salt of morpholinyl pyridinopyrimidone derivative
12/18/2013CN103450191A Organic semiconductor material, preparation method and electroluminescent device
12/18/2013CN103450190A Organic semiconductor material, preparation method and electroluminescent device
12/18/2013CN103450189A Organic semiconductor material, preparation method and electroluminescent device
12/18/2013CN103450188A Organic semiconductor material, preparation method and electroluminescent device
12/18/2013CN103450152A Anti-tumor medicine in double-aryl urea structure based on indazole, indole, azaindazole or azaindole
12/18/2013CN103449947A Pre-purification method before sublimation and purification of OLED (organic light emitting diode) material
12/18/2013CN102477034B 1-methyl-beta-carboline-3-carboxylic acid modified by amino acid as well as synthesizing method and application thereof
12/18/2013CN102143958B Pyridazine derivatives as SMO inhibitors
12/18/2013CN101842373B 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives as cathepsin inhibitors
12/18/2013CN101522679B Fluorinated catharanthine derivatives, their preparation and their utilisation as vinca dimeric alkaloid precursors
12/17/2013US8609846 Naphthalene monoimide derivatives and use thereof as photosensitizers in solar cells and photodetectors
12/17/2013US8609845 Pyrrolidine inhibitors of IAP
12/17/2013US8609687 Triazolopyridine JAK inhibitor compounds and methods
12/17/2013US8609686 Substituted azabicyclic compounds and the use thereof
12/17/2013US8609666 2-morpholino-pyrido[3,2-D]pyrimidines
12/17/2013US8609656 Heteroarylphenylurea derivative
12/17/2013US8609653 Azaindole compounds and methods for treating HIV
12/17/2013US8609650 Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
12/17/2013US8609259 Organic electroluminescent device and platinum compound
12/17/2013CA2749114C Heteroatom-containing cyclic compound
12/17/2013CA2697051C Substituted-quinoxaline-type piperidine compounds and the uses thereof
12/17/2013CA2618550C Indole derivatives as crth2 receptor antagonists
12/17/2013CA2611893C Tetrahydroquinolines for use as modulators of the mitotic motor protein eg5
12/17/2013CA2568993C S-tenatoprazole sodium monohydrate salt and the use thereof in the form of a proton pump inhibitor
12/12/2013WO2013184757A1 Compounds and compositions for modulating egfr activity
12/12/2013WO2013184698A1 Solid forms of an antiviral compound
12/12/2013WO2013184202A1 Fbxo3 inhibitors
1 ... 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 ... 646